Scalp Psoriasis
27
0
0
24
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Published Results
12 trials with published results (44%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 27 trials
100.0%
+13.5% vs benchmark
52%
14 trials in Phase 3/4
50%
12 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 24 completed trials
Clinical Trials (27)
Daxxin Psoriasis Shampoo PMCF
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis
Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis
Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis
Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis
Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis
Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp
Evaluate the Efficacy and Safety of Boroda Supramolecular Active Zinc in the Treatment of Scalp Psoriasis
Subject Preference for Scalp Psoriasis Treatment
A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis
To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis
Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product